Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Teleflex Interventional leader sees resorbables as ‘the next frontier’ of PCI

October 26, 2026 By Jim Hammerand

An image of the Teleflex Freesolve RMS resorbable magnesium scaffold.

The Teleflex Freesolve RMS (resorbable magnesium scaffold) uses proprietary magnesium alloy and bioabsorbable coating technology to provide vessel support during and after implantation. [Image courtesy of Teleflex]

Jason Fontana got good news to celebrate in his first weeks as president and GM of the interventional business at Teleflex.

In October 2026, the Teleflex Freesolve RMS (resorbable magnesium scaffold) won FDA Breakthrough Device designation for percutaneous coronary intervention (PCI), which should fast-track the drug-eluting stent’s regulatory review in the U.S.

The catheter-delivered device already had a CE mark and was also available in Asian-Pacific, South American and Middle Eastern countries. In 2024, Freesolve RMS developer Biotronik (which sold the technology with the rest of the its Vascular Intervention Business to Teleflex in 2025) secured breakthrough designation for below-the-knee treatment of chronic limb-threatening ischemia (CLTI).

Fontana — who is a member of Medical Design & Outsourcing’s new Medtech Innovation Board — discussed the Freesolve RMS device, the resorbable technology behind it and the “next frontier” of PCI in an MDO interview. The following has been lightly edited for length and clarity.

MDO: I know you’ve just joined Teleflex, but what can you tell us about this product’s R&D journey?

Fontana: “What’s really cool and exciting about Freesolve is the team at Biotronik and then ultimately Teleflex set out to solve this age-old problem of how to deliver a product with contemporary drug-eluting stents, how to safely keep the scaffold open during the time the drug is being eluted, and how to make it go away when it’s done its job. This journey was first understanding. Then they developed the proprietary BIOmag absorbable magnesium scaffold to deliver like a standard drug-eluting stent, but be in place for long enough to provide that scaffold and provide that drug, and then reabsorb. This dynamic required some unbelievable engineering and unbelievable preclinical and clinical work. For me, it’s exciting to be at the end of one part of the journey and the beginning of the next part of the journey with Breakthrough Device designation.”

A close-up illustration of the Teleflex Freesolve RMS resorbable magnesium scaffold.

The Teleflex Freesolve RMS has a scaffold made of absorbable magnesium and aluminum with an oval Tantalum marker at each end. [Image courtesy of Teleflex]

What’s the opportunity in terms of patient population and total addressable market (TAM), if you can discuss that yet?

Fontana: “Not yet from a TAM perspective, but there’s unfortunately millions of people with coronary disease and millions of stents and millions of PCIs done each year. This opportunity is unique because patients and physicians are searching for this nothing-left-behind dynamic. We’ve seen that with the uptick of drug-coated balloons and the advancement of drug-coated balloon technology, which has been in Europe forever with two recently approved in the U.S. and more under study, and we have one that is now coming to the United States. Ultimately, if physicians could have something they’re used to delivering that is there when it needs to be there and then goes away, I think it’s the next frontier of PCI, which is exciting. We have set of clinical trials to really define the evidence to define the opportunity. We’ve done our first-in-human trial, BIOMAG-I, completed enrollment of our nearly 2,000-patient, randomized BIOMAG-II outside the U.S., and now we’re in the enrollment of our third trial, which will be used for U.S. FDA approval, BIOMAG-III. Sometimes when people think about new technologies, they generally don’t fully grasp the amount of evidence that’s being generated behind them, and we’re really committed to that going forward. So not necessarily the TAM answer, but the opportunity is available just from a PCI perspective, and we’re generating that evidence now.”

What’s the importance of leaving nothing behind for patients?

A photo of Jason Fontana.

Teleflex Interventional President and GM Jason Fontana [File photo courtesy of Medtronic]

Fontana: “When you think of this concept — and maybe Jim, I’m kind of saying it out loud for the first time because I’m still learning about the technology — but we have PCI, which we’ve been doing for almost 50 years now and we’ve evolved to where we have great stents and we’re thinking about drug-coated balloons. But I think the piece that’s been missing in this whole dynamic that we’re always trying to get to is can we put a stent in place and when it does its job, does it go away? I think we are on the next frontier of maybe resorbable PCI or restorable PCI where you treat the vessel when it needs to be treated, but you’re not putting in a permanent scaffold. The vessel no longer has a scaffold in there. For physicians, you place the stent, you know you’re treating the culprit lesion and if you have to come back at some point, that vessel is now open and there’s no metal to deal with. For a patient, your vessel’s treated and now there’s nothing there for the long term. I think we’re on the next frontier of what PCI will be with Freesolve.”

What’s special about this magnesium alloy and the absorbable coating that you’re using in Freesolve RMS and elsewhere in your portfolio?

Fontana: “It’s pretty neat, right? BIOmag is our proprietary magnesium alloy that goes away pretty much in that roughly one-year timeframe. What’s super cool is we’ve also combined that with a polymer called BIOlute, which elutes sirolimus — our drug — and that polymer goes away. So we have the polymer going away after eluting the drug and the whole scaffolding going away, two proprietary nothing-left-behind approaches with our technology.”

A cutaway illustration of the Teleflex Freesolve RMS resorbable magnesium scaffold.

The Teleflex Freesolve RMS (resorbable magnesium scaffold) uses a bioabsorbable Poly-L-Lactide (PLLA) coating to release a limus drug. [Image courtesy of Teleflex]

Read more: Bioabsorbable polymers for implantable medical devices

Are there other potential applications of these technologies?

Fontana: “One of the immediate ones is we also have Breakthrough Device designation for the use of Freesolve in the peripheral space below the knee. That becomes another really interesting area as we approach thinking about vessels and leaving nothing behind. With both coronary and peripheral applications, it’s very intriguing. I think there are others behind that, but we’re still thinking through the application of this technology in that area.”

Teleflex is the world’s 55th largest medical device company according to Medical Design & Outsourcing‘s 2026 Medtech Big 100 ranking by revenue.

About The Author

Jim Hammerand

Jim Hammerand is the managing editor of Arrowfly's Medical Design & Outsourcing, where he leads coverage of medtech innovation, design, engineering and manufacturing. He also reports breaking news at Arrowfly's MassDevice and contributes to our DeviceTalks podcasts and live events. Hammerand has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then as managing editor of the Puget Sound Business Journal in Seattle. He holds degrees in journalism and management from the University of Minnesota and has won journalism awards from the Society of Professional Journalists, American Society of Business Publication Editors, and Trade, Association, Business Publications International. Connect with him on LinkedIn or by email at [email protected].

Related Articles Read More >

The Virtuoso System endoscope tip with manipulators,
Tiny, superelastic nitinol arms make this breakthrough surgical robot possible
A photo of Philips Chief Medical Officer Dr. Carla Goulart Peron.
“We cannot go backwards,” Philips CMO says on leadership, diversity and AI
Confluent Medical Technologies buys Northern Nitinol 
Stryker's next CEO Spencer Stiles at The Medtech Conference.
What Stryker’s next CEO learned from the cyberattack
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 Arrowfly, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe